Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 1 1

Status

Completed 2Withdrawn 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Tumor-Agnostic 4Thoracic 3Breast 3Gynecologic 2Other solid neoplasm 1Lymphoid 1CNS 1

Conditions

Breast Neoplasms 3Neoplasms 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Trastuzumab 732Paclitaxel 695Cyclophosphamide 647Docetaxel 560Capecitabine 486Letrozole 437Fulvestrant 400Carboplatin 398Doxorubicin 341Tamoxifen 308Anastrozole 279pembrolizumab 274exemestane 258Epirubicin 251pertuzumab 240Radiotherapy 239palbociclib 224Bevacizumab 222Gemcitabine 215Vinorelbine 197Lapatinib 181130-nm albumin-bound paclitaxel 172Magnetic Resonance Spectroscopy 164Albumin-Bound Paclitaxel 157eribulin 154Surveys and Questionnaires 152Exercise 151Drug Therapy 141Taxes 134Fluorouracil 133

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
XL147 × Breast × Clear all
NCT01042925 2016-06-03

Study of XL147 (SAR245408) in Combination With Trastuzumab or Paclitaxel and Trastuzumab in Subjects With Metastatic Breast Cancer Who Have Progressed on a Previous Trastuzumab-based Regimen

Sanofi

Phase 1/2 Completed
42 enrolled
Breast

Breast Neoplasms

NCT01082068 2016-06-03

Study of XL147 (SAR245408) or XL765 (SAR245409) in Combination With Letrozole in Subjects With Breast Cancer

Sanofi

Phase 1/2 Completed
72 enrolled
Breast

Breast Neoplasms

NCT00704392 2015-08-20

Safety Study of XL647 and XL147 Administered in Combination Daily in Adults With Solid Tumors

Exelixis

Phase 1 Withdrawn
BreastThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡